Stocks of the Hour: Chimeric Therapeutics, Apollo Minerals, Caspin Resources
Chimeric Therapeutics (ASX:CHM) announced the execution of a clinical study agreement with The University of Texas MD Anderson Cancer Center to support the “ADVENT-AML” Phase 1B study, for patients with newly diagnosed Acute Myeloid Leukaemia. In response, Jason B Litten, MD, Chief Medical Officer, stated, “By combining CHM 0201 with the current standard of care […]
Stocks of the Hour: Chimeric Therapeutics, Apollo Minerals, Caspin Resources Read More »









